YMAB Stock Overview
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
Y-mAbs Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.19|
|52 Week High||US$20.48|
|52 Week Low||US$2.94|
|1 Month Change||-53.08%|
|3 Month Change||-72.97%|
|1 Year Change||-75.57%|
|3 Year Change||-87.59%|
|5 Year Change||n/a|
|Change since IPO||-82.54%|
Recent News & Updates
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts DramaticallyAug 13
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?May 12
Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth PlansDec 09
Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New ForecastsAug 11
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Released Its Second-Quarter Earnings: Here's What Analysts ThinkAug 09
Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn SituationJul 07
These Analysts Just Made A Massive Downgrade To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) EPS ForecastsMar 01
Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn SituationJan 28
Have Insiders Sold Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Recently?Dec 06
Who Has Been Selling Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?Nov 18
|YMAB||US Biotechs||US Market|
Return vs Industry: YMAB underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: YMAB underperformed the US Market which returned -18.5% over the past year.
|YMAB Average Weekly Movement||22.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: YMAB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: YMAB's weekly volatility has increased from 16% to 23% over the past year.
About the Company
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Y-mAbs Therapeutics, Inc. Fundamentals Summary
|YMAB fundamental statistics|
Is YMAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YMAB income statement (TTM)|
|Cost of Revenue||US$7.01m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.06|
|Net Profit Margin||-307.75%|
How did YMAB perform over the long term?See historical performance and comparison